References
- Melmed S. Physiology of growth hormone. UpToDate. In: Rose BD,
editor. UpToDate. 2008. Waltham, MA.
- Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of
activation and clinical implications. Nature reviews
Endocrinology. 2010;6(9):515–25.
- FDA. FDA Drug Safety Podcast for Healthcare Professionals: Ongoing
safety review of Recombinant Human Growth Hormone (somatropin) and
possible increased risk of death.
- Plotkin D, Ng J, Farmer M, Gelato M, Kaiser F, Kiel D, Korenman S,
McKeever C, Munoz, Schwartz R, Krupa D, Gormley G, Bach MA. Use of
MK-677, an oral GH secretagogue in frail elderly subjects. Endocrinol
Metab 1997;4(SupplA):35–36.
- Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J,
Stevens TE, et al. Growth hormone and sex steroid administration in
healthy aged women and men: a randomized controlled trial. JAMA
2002;288:2282–92.
- Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration; 2011.
- Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA,
et al. Growth hormone regulation of p85 alpha expression and
phosphoinositide 3-kinase activity in adipose tissue: mechanism for
growth hormone-mediated insulin resistance. Diabetes 2007;56:1638–46.
- Turżańska
K, Drelich
M, Posturzyńska
A. Protein and physical activity in prevention and treatment
of sarcopenia.
Wiad
Lek. 2019;72(9 cz 1):1660-1666.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin
mimetic on body composition and clinical outcomes in healthy older
adults: a randomized trial. Ann Intern Med .
2008;149(9):601–611. doi:10.7326/0003-4819-149-9-200811040-00003.
- Sigalos
JT, Pastuszak
AW. The Safety and Efficacy of Growth Hormone Secretagogues.
Sex Med Rev. 2018
Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8.
- Campbell
GA, Patrie
JT, Gaylinn
BD, Thorner
MO, Bolton
WK. Oral ghrelin receptor agonist MK-0677 increases serum
insulin-like growth factor 1 in hemodialysis patients: a randomized
blinded study.
Nephrol Dial
Transplant. 2018 Mar 1;33(3):523-530. doi: 10.1093/ndt/gfw474.
- Adunsky
A, Chandler
J, Heyden
N, Lutkiewicz
J, Scott
BB, Berd
Y, Liu
N, Papanicolaou
DA. MK-0677 (ibutamoren mesylate) for the treatment of patients
recovering from hip fracture: a multicenter, randomized,
placebo-controlled phase IIb study.
Arch Gerontol
Geriatr. 2011 Sep-Oct;53(2):183-9. doi:
10.1016/j.archger.2010.10.004. Epub 2010 Nov 9.
- Bach
MA, Rockwood
K, Zetterberg
C, Thamsborg
G, Hébert
R, Devogelaer
JP, Christiansen
JS, Rizzoli
R, Ochsner
JL, Beisaw
N, Gluck
O, Yu
L, Schwab
T, Farrington
J, Taylor
AM, Ng
J, Fuh
V; MK
0677 Hip Fracture Study Group. The effects of MK-0677, an oral growth
hormone secretagogue, in patients with hip fracture.
J Am Geriatr
Soc. 2004 Apr;52(4):516-23.
- Murphy
MG, Bach
MA, Plotkin
D, Bolognese
J, Ng
J, Krupa
D, Cerchio
K, Gertz
BJ. Oral administration of the growth
hormone secretagogue MK-677 increases markers of bone turnover in
healthy and functionally impaired elderly adults. The MK-677 Study
Group. J Bone
Miner Res. 1999 Jul;14(7):1182-8.
- Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et
al. Stimulation of the growth hormone (GH)-insulin-like growth factor
I axis by daily oral administration of a GH secretogogue (MK-677) in
healthy elderly subjects. The Journal of clinical endocrinology and
metabolism. 1996;81(12):4249–57.